SAGA Diagnostics remote jobs and company guide

At SAGA Diagnostics, we are at the forefront of revolutionizing the earlier detection of Molecular Residual Disease (MRD) to inform personalized treatment for patients. Our proprietary MRD testing platform aids patients, oncologists, clinical researchers, and drug developers to confidently detect residual disease post-curative intent therapy and monitor response to therapy with unprecedented sensitivity and specificity.

Our accomplished team comprises some of the industry's most seasoned liquid biopsy experts, united in a shared promise to detect and intercept molecular residual disease as early as possible for every patient. SAGA has developed a unique tumor-informed MRD platform that utilizes a hybrid of next-generation sequencing (NGS) and novel digital PCR technology. This innovative approach tracks patient-specific structural variants to detect MRD early and accurately, providing an essential tool for patient care.